Adaptimmune Quarterly report pursuant to Section 13 or 15(d)

Other current assets

3 Months Ended

Mar. 31, 2023

Note 8 — Other current assets

Other current assets consisted of the following (in thousands):


	March 31,		December 31,
	2023		2022
Research and development credits receivable	$	36,363	$	30,162
Prepayments		6,787		9,472
Clinical materials		1,310		1,279
VAT receivable		355		490
Other current assets		1,664		1,927
	$	46,479	$	43,330